Skip to content

Hero image: A woman in a respectful vulvar-pain consultation with a specialist listening attentively

All insights

Intimacy and Identity

Vulvodynia: Name the Pain, Exclude Other Causes and Build a Layered Plan

11 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based guide to vulvodynia classification, cotton-swab assessment, pelvic-floor care, psychological support and treatment uncertainty.

Evidence at a glance

8.3%

weighted vulvodynia prevalence in one population-based study

The study involved adult women in southeast Michigan and used a validated survey approach. Only a small minority meeting criteria had received the diagnosis, but the estimate should not be generalized unchanged to every population. [3]

Prevalence and Demographic Characteristics of Vulvodynia in a Population-Based Sample

Vulvodynia is persistent vulvar pain without a clear specific cause

Consensus terminology defines vulvodynia as vulvar pain lasting at least three months without a clear identifiable cause, although potential associated factors may be present. [1] Pain may be burning, stinging, rawness, aching or irritation. It can be localized to the vestibule or clitoris, generalized, provoked by touch, spontaneous or mixed.

The diagnosis is not the same as saying nothing is wrong. It follows assessment for infections, inflammatory skin disease, hormonal tissue change, neurological injury, trauma and neoplasia. A person can have vulvodynia and a specific vulvar disorder at the same time, which is why a new lesion or symptom change deserves review.

  • Describe location, trigger, onset and timing.
  • Include tampon use, sitting, clothing and sexual touch.
  • Record whether pain began with first penetration or later.
  • Do not assume a normal visual examination means no pain disorder.

Diagnosis starts with permission, history and targeted examination

ACOG recommends a detailed medical, surgical, sexual, allergy and treatment history. [1] Examination can assess vulvar and vaginal tissue, with testing for infection when indicated. A gentle cotton-swab test maps pain and helps distinguish localized from generalized patterns. The patient should control the pace and may decline any part.

Pelvic-floor and musculoskeletal assessment can identify overactivity, tenderness and referred pain. [1] Biopsy is reserved for suspicious skin findings or diagnostic uncertainty, not routine confirmation of vulvodynia. Repeated empiric antifungal treatment without evidence can irritate tissue and delay the correct diagnosis.

  • Explain every examination step before contact.
  • Use infection tests only when clinically indicated.
  • Map pain rather than provoking maximum pain.
  • Assess pelvic-floor and adjacent musculoskeletal contributors.

A biopsychosocial model does not make the pain psychological

Vulvodynia may involve peripheral nerve sensitivity, central pain processing, pelvic-floor dysfunction, inflammatory pathways, hormonal factors and learned guarding. NIH identifies multiple active research hypotheses and no single established cause. [2] Anxiety, depression, trauma or relationship strain can amplify or result from pain without being the sole explanation.

This model supports treating several contributors at once. Education can reduce fear; pelvic-floor therapy can address overactivity; cognitive behavioral care can support coping and graded return to valued activity; and medical treatment can target tissue or neuropathic symptoms. The plan should validate pain and never require disclosure of trauma as a condition of care.

  • Treat pain as real regardless of visible findings.
  • Ask about mental health without assigning causation.
  • Use trauma-informed and culturally safe care.
  • Set functional goals chosen by the patient.

Treatment is layered because no single option works for everyone

ACOG recommends individualized multidisciplinary care that may include vulvar self-care, pelvic-floor physical therapy, biofeedback, psychological or sex therapy, oral or topical medicines, injections and selected procedures. [1] Evidence for many medications is limited. NICHD notes that several randomized studies did not show benefit for commonly used antidepressant or topical regimens over comparison care. [4]

Localized provoked vestibulodynia that persists despite conservative care may be considered for vestibulectomy in selected patients. Surgery is not appropriate for generalized pain and requires discussion of recovery, scarring, persistent pain and sexual goals. Treatment should be changed when it adds burning, sedation or other burden without meaningful benefit.

  • Begin with education and gentle vulvar care.
  • Match pelvic-floor therapy to overactivity and pain.
  • Use medication trials with a stop rule.
  • Reserve surgery for carefully selected localized disease.

Intimacy goals are defined by the person, not penetration

Pain can narrow intimacy through anticipation, guarding and avoidance. Care can preserve affectionate touch, pleasure and communication without making vaginal penetration the required endpoint. Lubrication, pacing, positional adaptation, graded exposure and partner education may help when desired. Consent remains active throughout every encounter. [1][5][6]

Sex therapy can address fear, communication and changed sexual scripts while pelvic care addresses physical contributors. A partner can participate with permission but should not become the primary recipient of the treatment goal. Success may mean pain-free sitting, comfortable clothing, an examination, tampon use, chosen sexual activity or reduced flare frequency. [1][5]

  • Define valued activities beyond intercourse.
  • Use graded exposure only with consent and control.
  • Include partners when the patient wants this.
  • Avoid pressure to tolerate pain for relationship goals.

Measure function and keep diagnostic vigilance

Follow-up should track pain location, trigger and intensity alongside sitting, clothing, exercise, sleep, mood and sexual function. A pain diary can identify flares, but intensive logging may increase attention to pain for some people. Measures should be selected collaboratively and used to guide treatment rather than prove suffering.

New bleeding, ulceration, pigment change, discharge, focal mass, neurological deficit or systemic symptoms warrants reassessment for another condition. Current reviews emphasize substantial evidence gaps and the need for better phenotyping and trials. [5] Honest uncertainty is preferable to serial unsupported treatments or claims of a single hidden cause.

  • Track the outcomes that matter to daily life.
  • Re-examine new or changing tissue findings.
  • Review benefits and adverse effects of each component.
  • Coordinate gynecology, pelvic health, pain and psychological care.

What the evidence cannot yet answer

  • Population prevalence estimates use different screening and confirmation methods and may not generalize across cultures or ages.
  • Vulvodynia likely includes several mechanisms, and no biomarker currently selects a reliable treatment.
  • Many treatment studies are small, use different subtypes and have limited follow-up.
  • Some medications commonly used in practice have weak or conflicting trial evidence.

Questions worth taking into care

  1. Which specific causes of vulvar pain have been considered and excluded?
  2. How is my pain classified by location, trigger and timing?
  3. Is pelvic-floor overactivity or referred musculoskeletal pain present?
  4. What is the goal and stop rule for each treatment trial?
  5. Which functional and intimacy outcomes matter most to me?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Persistent Vulvar Pain

    American College of Obstetricians and Gynecologists · 2016

  2. [2]
    Vulvodynia and NIH Women's Health Research

    National Institutes of Health · 2026

  3. [3]
  4. [4]
    Vulvodynia Research and Treatment

    Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2025

  5. [5]
    Evaluation and Treatment of Vulvodynia: State of the Science

    Journal of Midwifery and Women's Health · 2023

  6. [6]
    Vulvodynia

    Nature Reviews Disease Primers · 2020

Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.